Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
oleh: Po-Lan Su, MD, Chien-Yu Lin, MD, Yi-Lin Chen, MS, Wan-Li Chen, MS, Chien-Chung Lin, MD, PhD, Wu-Chou Su, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2021-08-01 |
Deskripsi
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.